Skip to main
COGT
COGT logo

COGT Stock Forecast & Price Target

COGT Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 27%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Cogent Biosciences is poised for significant advancement in 2025, positioning itself as a potential target for mergers and acquisitions due to its strategic developments in precision therapies. The company’s investigational drug, bezuclastinib, has demonstrated promising data from the APEX, PEAK, and SUMMIT trials, indicating its potential as a competitive treatment option across various malignancies. Such positive clinical outcomes, in conjunction with anticipated growth, enhance Cogent's attractiveness to investors and the broader market.

Bears say

Cogent Biosciences Inc. is projected to experience a significant net loss of $2.28 per share for the full year 2025, indicating ongoing financial challenges. Key risks affecting the company's outlook include potential negative clinical data, slower than anticipated development timelines, setbacks in later-stage trials, and difficulties in obtaining regulatory approvals for its therapies. Additionally, lower-than-expected commercial success and long-term dilution risk further contribute to the negative sentiment surrounding the company’s financial prospects.

COGT has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 27% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cogent Biosciences, Inc. (COGT) Forecast

Analysts have given COGT a Buy based on their latest research and market trends.

According to 11 analysts, COGT has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cogent Biosciences, Inc. (COGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.